Tag #Alzheimer's

Showing 61 to 69 of 69 results

cnn.com

🌐 75% Global Worthiness

Nov 20, 04:05

Aerobic Exercise May Reduce Dementia Risk

A new study reveals that regular aerobic exercise can significantly reduce the risk of dementia, even for those genetically predisposed to Alzheimer's disease.

Aerobic Exercise May Reduce Dementia Risk

A new study reveals that regular aerobic exercise can significantly reduce the risk of dementia, even for those genetically predisposed to Alzheimer's disease.

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the limitations of the study, and how should its results be interpreted?

The study highlights the importance of cardiorespiratory fitness in delaying the onset of dementia, with the most fit individuals experiencing a 1.5-year delay and a 35% lower risk for those genetically predisposed to Alzheimer's.

theguardian.com

🌐 % Global Worthiness

Nov 16, 19:09

Cancer and Alzheimer's: An Unexpected Link

Studies reveal an inverse relationship between cancer and Alzheimer's disease, where having one condition may reduce the risk of developing the other. Researchers explore the underlying biological mechanisms and potential implications.

Cancer and Alzheimer's: An Unexpected Link

Studies reveal an inverse relationship between cancer and Alzheimer's disease, where having one condition may reduce the risk of developing the other. Researchers explore the underlying biological mechanisms and potential implications.

Progress

0% Bias Score

ShareSaveArticle

12345678910

Previous 1 of 10 Next

What is the practical relevance of these findings?

The findings offer a small comfort for cancer survivors, suggesting a potentially lower risk of Alzheimer's disease. However, more research is needed to understand the intricacies of the relationship before any practical applications can be developed, including which specific types of cancer and dementia are involved.

lemonde.fr

🌐 % Global Worthiness

Nov 15, 16:03

EMA Approves Alzheimer's Drug Leqembi

The European Medicines Agency approves Leqembi, a new Alzheimer's drug, with strict conditions to mitigate serious side effects.

EMA Approves Alzheimer's Drug Leqembi

The European Medicines Agency approves Leqembi, a new Alzheimer's drug, with strict conditions to mitigate serious side effects.

Progress

0% Bias Score

ShareSaveArticle

12345678910

Previous 1 of 10 Next

How will access to Leqembi be managed?

The drug will be available through a controlled access program to ensure it's used only in the recommended patient population. This program requires MRI monitoring for side effects before treatment and at specific intervals thereafter.

welt.de

🌐 % Global Worthiness

Nov 15, 04:06

Lecanemab: EMA Approval and Limitations

EMA approves Lecanemab, a new Alzheimer's drug targeting amyloid plaques, but with limitations due to side effects and treatment complexity.

Lecanemab: EMA Approval and Limitations

EMA approves Lecanemab, a new Alzheimer's drug targeting amyloid plaques, but with limitations due to side effects and treatment complexity.

Progress

0% Bias Score

ShareSaveArticle

12345678910

Previous 1 of 10 Next

What are the limitations and restrictions placed on the use of Lecanemab by the EMA?

The EMA's approval of Lecanemab is limited to patients with mild cognitive impairment or mild dementia in the early stages of Alzheimer's and those with one or zero copies of the ApoE4 gene to mitigate risks of serious side effects like brain swelling and bleeding.

foxnews.com

🌐 % Global Worthiness

Nov 8, 13:29

Active Lifestyle Helps Manage Alzheimer's Symptoms

A 90-year-old man with Alzheimer's maintains an active lifestyle to manage his symptoms, highlighting the potential benefits of physical activity and social engagement in slowing cognitive decline.

Active Lifestyle Helps Manage Alzheimer's Symptoms

A 90-year-old man with Alzheimer's maintains an active lifestyle to manage his symptoms, highlighting the potential benefits of physical activity and social engagement in slowing cognitive decline.

Progress

0% Bias Score

ShareSaveArticle

12345678910

Previous 1 of 10 Next

How does physical activity potentially help Alzheimer's patients?

Doctors suggest that physical activity increases blood flow to the brain, potentially slowing cognitive decline in Alzheimer's patients, although it won't stop the disease's progression.

dailymail.co.uk

🌐 65% Global Worthiness

Nov 19, 04:03

Loss of Smell: Early Warning Sign for Dementia?

Loss of smell may be an early indicator of Alzheimer's and Parkinson's diseases. While common causes exist, studies reveal a strong correlation with dementia risk.

Loss of Smell: Early Warning Sign for Dementia?

Loss of smell may be an early indicator of Alzheimer's and Parkinson's diseases. While common causes exist, studies reveal a strong correlation with dementia risk.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential causes of loss of smell, and how common is it?

Loss of smell, or anosmia, can be an early warning sign of neurodegenerative diseases like Alzheimer's and Parkinson's, potentially appearing years before diagnosis.

dw.com

🌐 % Global Worthiness

Nov 15, 22:08

Lecanemab and the fight against Alzheimer's

New research sheds light on the cause of cell death in Alzheimer's disease, potentially opening new avenues for treatment, while the drug Lecanemab offers some hope in slowing progression.

Lecanemab and the fight against Alzheimer's

New research sheds light on the cause of cell death in Alzheimer's disease, potentially opening new avenues for treatment, while the drug Lecanemab offers some hope in slowing progression.

Progress

0% Bias Score

ShareSaveArticle

12345678910

Previous 1 of 10 Next

What is Lecanemab and what is its current status?

Lecanemab is a new drug that shows promise in slowing the progression of Alzheimer's disease, although it cannot cure it. It targets amyloid protein, a key factor in the disease's development.

liberation.fr

🌐 % Global Worthiness

Nov 15, 13:09

EMA Approves Leqembi for Alzheimer's

The European Medicines Agency approves Leqembi, a new Alzheimer's treatment to reduce cognitive decline in early-stage patients. The drug targets amyloid plaques in the brain and has already received approvals in other countries.

EMA Approves Leqembi for Alzheimer's

The European Medicines Agency approves Leqembi, a new Alzheimer's treatment to reduce cognitive decline in early-stage patients. The drug targets amyloid plaques in the brain and has already received approvals in other countries.

Progress

0% Bias Score

ShareSaveArticle

12345678910

Previous 1 of 10 Next

What is Leqembi and what is its purpose?

The European Medicines Agency (EMA) approved Leqembi, a new treatment to reduce cognitive decline in Alzheimer's patients. It's for patients in the early stages of the disease, not those with advanced Alzheimer's.

elmundo.es

🌐 % Global Worthiness

Nov 13, 07:10

Alzheimer's Research: Advancements and Challenges

This article discusses the latest advancements and challenges in Alzheimer's drug development, focusing on various therapeutic targets, drug repurposing, and the regulatory landscape.

Alzheimer's Research: Advancements and Challenges

This article discusses the latest advancements and challenges in Alzheimer's drug development, focusing on various therapeutic targets, drug repurposing, and the regulatory landscape.

Progress

0% Bias Score

ShareSaveArticle

12345678910

Previous 1 of 10 Next

Are there any examples of drug repositioning or repurposing for Alzheimer's treatment?

Besides biologicals, several drugs repurposed from other disease treatments (obesity, erectile dysfunction, malaria) are being tested for Alzheimer's, such as semaglutide and mirodefanil. These demonstrate the exploration of diverse therapeutic avenues.

Showing 61 to 69 of 69 results